Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 25, 2022

SELL
$7.06 - $25.52 $36,464 - $131,810
-5,165 Closed
0 $0
Q3 2021

Oct 21, 2021

BUY
$12.95 - $49.69 $66,886 - $256,648
5,165 New
5,165 $92,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Kessler Investment Group, LLC Portfolio

Follow Kessler Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kessler Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kessler Investment Group, LLC with notifications on news.